302 related articles for article (PubMed ID: 38757345)
1. Ferroptosis, pyroptosis and necroptosis in hepatocellular carcinoma immunotherapy: Mechanisms and immunologic landscape (Review).
Liu RJ; Yu XD; Yan SS; Guo ZW; Zao XB; Zhang YS
Int J Oncol; 2024 Jun; 64(6):. PubMed ID: 38757345
[TBL] [Abstract][Full Text] [Related]
2. Ferroptosis, necroptosis, and pyroptosis in anticancer immunity.
Tang R; Xu J; Zhang B; Liu J; Liang C; Hua J; Meng Q; Yu X; Shi S
J Hematol Oncol; 2020 Aug; 13(1):110. PubMed ID: 32778143
[TBL] [Abstract][Full Text] [Related]
3. Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy.
Gao W; Wang X; Zhou Y; Wang X; Yu Y
Signal Transduct Target Ther; 2022 Jun; 7(1):196. PubMed ID: 35725836
[TBL] [Abstract][Full Text] [Related]
4. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
5. Ferroptosis, necroptosis, and pyroptosis in the tumor microenvironment: Perspectives for immunotherapy of SCLC.
Niu X; Chen L; Li Y; Hu Z; He F
Semin Cancer Biol; 2022 Nov; 86(Pt 3):273-285. PubMed ID: 35288298
[TBL] [Abstract][Full Text] [Related]
6. Inflammation-related pyroptosis, a novel programmed cell death pathway, and its crosstalk with immune therapy in cancer treatment.
Hsu SK; Li CY; Lin IL; Syue WJ; Chen YF; Cheng KC; Teng YN; Lin YH; Yen CH; Chiu CC
Theranostics; 2021; 11(18):8813-8835. PubMed ID: 34522213
[TBL] [Abstract][Full Text] [Related]
7. Microecological regulation in HCC therapy: Gut microbiome enhances ICI treatment.
Liu X; Li S; Wang L; Ma K
Biochim Biophys Acta Mol Basis Dis; 2024 Aug; 1870(6):167230. PubMed ID: 38734322
[TBL] [Abstract][Full Text] [Related]
8. Cancer Immunotherapy - Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
Bai J; Liang P; Li Q; Feng R; Liu J
Recent Pat Anticancer Drug Discov; 2021; 16(2):239-248. PubMed ID: 33583384
[TBL] [Abstract][Full Text] [Related]
9. Immune Checkpoint Inhibitors as Monotherapy or Within a Combinatorial Strategy in Advanced Hepatocellular Carcinoma.
Guardascione M; Toffoli G
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32878115
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects.
Liu Z; Liu X; Liang J; Liu Y; Hou X; Zhang M; Li Y; Jiang X
Front Immunol; 2021; 12():765101. PubMed ID: 34675942
[TBL] [Abstract][Full Text] [Related]
11. Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research.
Tong X; Tang R; Xiao M; Xu J; Wang W; Zhang B; Liu J; Yu X; Shi S
J Hematol Oncol; 2022 Dec; 15(1):174. PubMed ID: 36482419
[TBL] [Abstract][Full Text] [Related]
12. Apoptosis, Pyroptosis, and Ferroptosis Conspiringly Induce Immunosuppressive Hepatocellular Carcinoma Microenvironment and γδ T-Cell Imbalance.
Hu Y; Chen D; Hong M; Liu J; Li Y; Hao J; Lu L; Yin Z; Wu Y
Front Immunol; 2022; 13():845974. PubMed ID: 35444645
[TBL] [Abstract][Full Text] [Related]
13. The progress of research on immune checkpoint inhibitor resistance and reversal strategies for hepatocellular carcinoma.
Kou L; Xie X; Chen X; Li B; Li J; Li Y
Cancer Immunol Immunother; 2023 Dec; 72(12):3953-3969. PubMed ID: 37917364
[TBL] [Abstract][Full Text] [Related]
14. CRISPR/Cas9 screen reveals that targeting TRIM34 enhances ferroptosis sensitivity and augments immunotherapy efficacy in hepatocellular carcinoma.
Yao F; Zhou S; Zhang R; Chen Y; Huang W; Yu K; Yang N; Qian X; Tie X; Xu J; Zhang Y; Baheti T; Xu J; Dai X; Hao X; Zhang L; Wang X; Li Q
Cancer Lett; 2024 Jul; 593():216935. PubMed ID: 38704136
[TBL] [Abstract][Full Text] [Related]
15. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
[TBL] [Abstract][Full Text] [Related]
16. Combination of ferroptosis and pyroptosis to construct a prognostic classifier and predict immune landscape, chemotherapeutic efficacy and immunosuppressive molecules in hepatocellular carcinoma.
Xu L; Zheng Q; Liu W
BMC Cancer; 2022 Mar; 22(1):229. PubMed ID: 35236323
[TBL] [Abstract][Full Text] [Related]
17. Selected Flavonols Targeting Cell Death Pathways in Cancer Therapy: The Latest Achievements in Research on Apoptosis, Autophagy, Necroptosis, Pyroptosis, Ferroptosis, and Cuproptosis.
Wendlocha D; Kubina R; Krzykawski K; Mielczarek-Palacz A
Nutrients; 2024 Apr; 16(8):. PubMed ID: 38674891
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitors in HCC: Cellular, molecular and systemic data.
Harkus U; Wankell M; Palamuthusingam P; McFarlane C; Hebbard L
Semin Cancer Biol; 2022 Nov; 86(Pt 3):799-815. PubMed ID: 35065242
[TBL] [Abstract][Full Text] [Related]
19. Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives.
Shen KY; Zhu Y; Xie SZ; Qin LX
J Hematol Oncol; 2024 Apr; 17(1):25. PubMed ID: 38679698
[TBL] [Abstract][Full Text] [Related]
20. Emerging Opportunities for Combining Locoregional Therapy with Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
Zeng P; Shen D; Zeng CH; Chang XF; Teng GJ
Curr Oncol Rep; 2020 Jun; 22(8):76. PubMed ID: 32596779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
